Upcoming Investor Conference Appearances
Revolution Medicines, Inc. (NASDAQ: RVMD), a progressive clinical oncology company, is gearing up to showcase its groundbreaking work in cancer therapies at two prominent investor conferences this November. This is an exciting time for the company as they engage with potential investors and share their innovative approaches to treating RAS-addicted cancers.
Details of the Conferences
The company’s participation in these notable events allows them to connect with key stakeholders who are interested in the evolving landscape of oncology. Below are the specifics of these crucial appearances:
Guggenheim 2nd Annual Healthcare Innovation Conference
Revolution Medicines will be a part of the Guggenheim conference. The fireside chat is scheduled for Tuesday, November 11 at 9:00 a.m. ET, presenting an important opportunity for discussions on their innovative pipeline.
Jefferies Global Healthcare Conference
Following the Guggenheim event, another key engagement will occur at the Jefferies Global Healthcare Conference. This fireside chat is set for Tuesday, November 18 at 9:30 a.m. GMT. Here, the company's leadership will delve into their targeted therapies and their impact on patient care.
Accessing Conference Materials
For those who are unable to attend these discussions live, Revolution Medicines will provide access to a live webcast of the events. Additionally, archived webcasts will be available on their website for an extended period, ensuring that all stakeholders can stay informed about the latest developments.
To explore these resources, simply visit their official website. They have made it a priority to keep investors and the public engaged with their ongoing initiatives.
About Revolution Medicines, Inc.
Revolution Medicines is at the forefront of developing cutting-edge therapies targeting RAS-addicted cancers, which have seen limited therapeutic options. Their R&D pipeline includes several promising candidates such as RAS(ON) inhibitors designed to tackle various oncogenic variants of RAS proteins effectively.
Their flagship products in clinical development include daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor, and elironrasib (RMC-6291), targeting RAS G12C, along with zoldonrasib (RMC-9805), which focuses on RAS G12D. Furthermore, the company is preparing to advance RMC-5127, a G12V-selective inhibitor, into clinical development soon. They are also exploring additional opportunities in RAS(ON) mutant-selective inhibitors, enhancing their impressive pipeline.
Media and Investor Relations
As Revolution Medicines expands its presence in the oncology arena, their media and investor relations contact points remain open for inquiries. They encourage anyone interested to reach out via their dedicated email addresses for pertinent questions or further information.
For media inquiries, contact: media@revmed.com
For investor inquiries, contact: investors@revmed.com
Frequently Asked Questions
What is the purpose of the investor conferences?
The conferences offer Revolution Medicines a platform to connect with investors and share insights about their innovative cancer therapies.
When are the conferences taking place?
The Guggenheim conference is on November 11, and the Jefferies conference is on November 18.
How can I access the webcasts?
Live webcasts will be available during the events, and recordings will be accessible on the company's website afterward.
What therapies is Revolution Medicines developing?
They are focused on RAS(ON) inhibitors, including daraxonrasib, elironrasib, and zoldonrasib, among others.
Who can I contact for more information?
For media and investor relations, you can email media@revmed.com and investors@revmed.com.
